Laurus Labs Limited — Call Transcript 2024

Jan 17, 2024

January 17, 2024

==> picture [452 x 76] intentionally omitted <==

To To The Corporate Relations Department The Listing Department BSE Limited National Stock Exchange of India Limited Phiroz Jeejeebhoy Towers, 25[th] Floor, Exchange Plaza, Dalal Street Bandra Kurla Complex, Bandra (East) Mumbai – 400001 Mumbai – 400 051 Code: 540222 Code: LAURUSLABS

Dear Sirs,

Sub: Q3 FY 24 Earnings conference call invite

Please find enclosed the Q3 FY 24 Earnings conference call invite for your information and records.

Thanking you,

Yours sincerely, For Laurus Labs Limited

VENKATESWAR Digitally signed by VENKATESWAR REDDY GOGIREDDY REDDY GOGIREDDY Date: 2024.01.17 14:35:52 +05'30'

G. Venkateswar Reddy Company Secretary & Compliance Officer

Encl: As above

==> picture [452 x 43] intentionally omitted <==

==> picture [114 x 37] intentionally omitted <==

LAURUS LABS LIMITED

Laurus Labs Ltd Q3 & 9M FY2024 Results Conference Call to be hosted on Wednesday, 24 January 2024 at 5:00pm IST

Laurus Labs Ltd. (Laurus), a leading research and development driven pharmaceutical company in India, will organize a conference call for Investors and Analysts, on Wednesday, 24 January 2024 at 5:00pm IST. The conference call will be initiated with a brief management discussion on the Q3 & 9M FY2024 results, followed by an interactive Question & Answer session. The call will be hosted by Antique Stock Broking.

Details of the conference call are as follows:

Date and Time	January24, 2024 - 5:00pm IST
Conference dial-in
PrimaryNumber	+91 22 6280 1342
SecondaryNumber	+91 22 7115 8243_Available all over India_
Singapore	800101 2045
HongKong	800964 448
Japan	00531161110
USA	1 866 746 2133
UK	0 808 101 1573
Diamond Pass	Event Link

==> picture [478 x 35] intentionally omitted <==

JANUARY 17, 2024

Press Release

==> picture [113 x 36] intentionally omitted <==

About Laurus | Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company with an aim to improve the quality of life for millions around the world. We have a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. We also offer integrated CMO and Contract Development and Manufacturing Organization (CDMO) services to Global Innovators from Clinical phase drug development to commercial manufacturing.

We are passionate about continuous technological advances for Smart and Green chemistry skills to driven efficiencies and sustainable manufacturing backed by proven regulatory inspection and quality foundation. Laurus employs 6500+ people, including around 1050+ scientists at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc. During FY2023 Laurus generated ₹ 6,041 crore in annual revenue and is listed on the BSE (Bombay Stock Exchange) and the NSE (National Stock Exchange) in India. Laurus' proactive stance to conduct business with utmost Transparency, Integrity and Respect for environment & communities have earned it a place in Governance benchmark, consistently Certified Great Place to Work and Rated “BBB” by leading MSCI ESG Ratings.

Corporate Identification No: L24239AP2005PLC047518

For more information about us, please visit http://www.lauruslabs.com or Contact particulars:

Investor Relations

Vivek Kumar Tel: +91 40 3980 4366 Email: investorrelations@lauruslabs.com

JANUARY 17, 2024

Press Release